What is STENTiT?
STENTiT is at the forefront of developing bioresorbable endovascular implants designed to revolutionize cardiovascular treatment. These advanced devices are engineered to interact with circulating blood cells, promoting the natural replacement of the implant with new vascular tissue. This innovative 'inside-out' healing mechanism aims to restore arterial function and offers a life-changing solution for millions worldwide. The company's high-potential approach has garnered international recognition and awards, positioning it as a leader in the medical device sector.
How much funding has STENTiT raised?
STENTiT has raised a total of $1.9M across 1 funding round:
Angel/Seed
$1.9M
Angel/Seed (2022): $1.9M with participation from NextGen Ventures and The BOM
Key Investors in STENTiT
NextGen Ventures
NextGen Ventures is an early-stage investor specializing in digital health and medtech, focusing on innovative startups in the Netherlands, Germany, and Belgium. They provide venture capital and strategic support to help companies scale and address unmet medical needs.
The BOM
The BOM (Brabantse Ontwikkelings Maatschappij) supports startups and scale-ups in Brabant through investment and networking, with a focus on health, advanced technologies, and sustainability. They provide financing and facilitate international expansion.
What's next for STENTiT?
With its recent major strategic investment, STENTiT is poised to accelerate its translational phases and scale its operations. The substantial capital infusion will likely fuel further research and development, clinical trials, and market penetration efforts. The company's ambition to establish a new standard in endovascular treatment is now more attainable, as it moves towards fulfilling its mission to significantly improve patient outcomes in cardiovascular care. This funding round signals a critical growth phase for STENTiT.
See full STENTiT company page
